Daily SPAC Update – Feb 16, 2024

by | Feb 16, 2024

CHEA DeSPACs to SELX. 4 SPAC Extension Votes: ENCP, IFIN, PPYA, CHAA. KWAC, MBTC, CHAA Set Deal Votes.

Boardroom Alpha SPAC Resources
Full SPAC Listing
SPAC SEC Filings
Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)

Daily SPAC Update

DeSPACs
CHEA -> SELX on Feb 16

TODAY’S EXTENSION VOTES
CHAA – CATCHA INVESTMENT CORP * 3 monthly options to extend to Mar 17, 2024
ENCP – ENERGEM CORP * extend to Aug 18, 2024
IFIN – INFINT ACQUISITION CORP * extend from Feb 23, 2024 to Nov 23, 2024
PPYA – PAPAYA GROWTH OPPORTUNITY CORP I * extend to Jan 19, 2025

SPAC VOTES SET
CHAA – CATCHA INVESTMENT CORP * Deal Vote Set: Mar 06, 2024 * trust $10.96
KWAC – KINGSWOOD ACQUISITION CORP * Deal Vote Set: Feb 22, 2024 * trust $12.99
MBTC – NOCTURNE ACQUISITION CORP * Deal Vote Set: Feb 27, 2024 * trust $11.72
CMCA – CAPITALWORKS EMERGING MARKETS ACQUISITION CORP * Extension Vote Set: Feb 29, 2024 * trust $11.07

SPAC VOTE RESULTS
BITE – BITE ACQUISITION CORP * Extend to Aug 17, 2024 * 518,880 redeemed * trust $10.70
LBBB – LAKESHORE ACQUISITION II CORP * Deal Approved * 1,246,563 redeemed

OTHER SPAC NEWS
KYCH – KEYARCH ACQUISITION CORPDeal & PIPE update
IVCP – SWIFTMERGE ACQUISITION CORPDeal terminated with HDL

YESTERDAY’S TOP SPAC GAINERS
16.10% ~ $ 50.56 | DWAC – Digital World Acquisition Corp. (Announced)
15.95% ~ $ 4.87 | LBBB – Lakeshore Acquisition II Corp. (Announced)
10.13% ~ $ 10.00 | WNNR – Andretti Acquisition Corp. (Announced)
4.30% ~ $ 11.41 | PTWO – Pono Capital Two, Inc. (Announced)
3.38% ~ $ 11.33 | ASCB – A SPAC II Acquisition Corp. (Pre-Deal)

YESTERDAY’S TOP SPAC LOSERS
-33.78% ~ $ 7.35 | SZZL – Sizzle Acquisition Corp. (Announced)
-12.57% ~ $ 9.01 | APAC – StoneBridge Acquisition Corp. (Announced)
-11.33% ~ $ 9.31 | SEPA – SEP ACQUISITION CORP (Announced)
-8.63% ~ $ 11.75 | OTEC – OceanTech Acquisitions I Corp. (Announced)
-4.85% ~ $ 11.18 | AVHI – Achari Ventures Holdings Corp. I (Announced)

 

Recent Analysis

CEO & CFO Moves Review – November 8, 2024

Explore last week’s CEO and CFO transitions at major public companies like Adial Pharmaceuticals, Affirm Holdings, Agrify Corp, and Dollar Tree. Learn about the new leaders taking charge amidst financial challenges, governance risks, and stock performance issues. This update covers executive shifts at companies facing shareholder pressures, regulatory scrutiny, and strategic reorganizations.

Daily SPAC Update – November 7, 2024

ACAB + Abpro SPAC Deal Vote. MCAA Extension Vote. FRLA and INTE Shareholders Extend. ROCL Deal and GLAC Extension Votes Set. ACAB Non-Redemption Agreement.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.